UCLA Researchers Develop Innovative Immunotherapy for Pancreatic Cancer
Scientists at UCLA have unveiled a new cell-based immunotherapy that could effectively target and eliminate pancreatic cancer cells, even when they have spread to other organs. This “off-the-shelf” treatment has shown promising results in preclinical studies involving mice, where it not only slowed down cancer progression but also extended survival rates.
Lead author Dr. Yanruide Lee described the approach as a multi-faceted attack, stating, “When cancer attempts to evade one attack route by altering its molecular signature, our therapy simultaneously strikes from various angles. Tumors simply can’t adapt quickly enough to this strategy.”
Development of the Therapy
Researchers engineered human stem cells into invariant natural killer T cells (NKT cells). By adding chimeric antigen receptors (CARs), these cells can effectively identify and engage pancreatic cancer cells.
These NKT cells are uniquely compatible with all immune systems, minimizing the risk of adverse reactions in patients. As a bonus, the use of donated blood stem cells allows for large-scale production, with a single donor potentially supplying enough cells for thousands of treatments.
Testing and Efficacy
The therapy was tested using various laboratory models, including those that mimicked how pancreatic cancer spreads to organs like the liver and lungs. Remarkably, these engineered CAR-NKT cells penetrated the tumors themselves, unlike many other immunotherapies that typically remain on the periphery.
What stands out is the ability of these immune cells to maintain their activity over time. In general, many immune cells struggle to function effectively when faced with the harsh environment of solid tumors, but these specially engineered cells continued to fight cancer longer.
The results were published in the journal PNAS, highlighting a significant shift in how pancreatic cancer might be treated. Senior author Dr. Lili Yang emphasized that this therapy could revolutionize approaches to this challenging disease.
Cost and Accessibility
The therapy is reportedly affordable, costing around $5,000 per dose, which is significantly less than some personalized treatments like CAR-T therapy. This affordability could make a substantial difference in accessibility for many patients.
Moreover, researchers believe this therapy could extend beyond pancreatic cancer; it targets proteins associated with breast, ovarian, and lung cancers, opening avenues for broader application.
Future Steps
Plans are in motion to submit an application to the FDA to initiate human trials, as previous tests were conducted solely in mouse models. Human tumors can be much more complex, as they can evolve and evade the targeted therapy, which raises challenges for treatment effectiveness.
While there’s great promise here, the long-term safety and potential side effects remain uncertain until the clinical trials commence. Additionally, logistical hurdles concerning the large-scale production of these immune cells present challenges that need to be addressed.
